IOVA

4.26

13.75% 0.515

Dopo l'orario di chiusura: 4.35 0.09 +2.11%

Iovance Biotherapeutics Inc (IOVA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché IOVA Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$3.745

Aprire:

$3.8

Volume 24 ore:

24.50M

Relative Volume:

1.90

Capitalizzazione di mercato:

$1.75B

Reddito:

$241.53M

Utile/perdita netta:

$-389.92M

Rapporto P/E:

-3.4634

EPS:

-1.23

Flusso di cassa netto:

$-323.54M

1 W Prestazione:

+11.23%

1M Prestazione:

+74.59%

6M Prestazione:

+93.64%

1 anno Prestazione:

+8.67%

Intervallo 1D:

$3.73

$4.28

Intervallo di 1 settimana:

$3.50

$4.28

Portata 52W:

$1.6385

$4.35

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Nome

Iovance Biotherapeutics Inc

Settore

Healthcare (1106)

Industria

Biotechnology (621)

Telefono

(650) 260-7120

Indirizzo

825 INDUSTRIAL ROAD, SAN CARLOS

Dipendente

975

Cinguettio

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

IOVA's Discussions on Twitter

Compare IOVA vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
IOVA Iovance Biotherapeutics Inc	4.26	1.54B	241.53M	-389.92M	-323.54M	-1.23
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-07-15	Downgrade	Goldman	Neutral → Sell
2025-05-16	Downgrade	UBS	Buy → Neutral
2025-05-12	Downgrade	Truist	Buy → Hold
2025-05-09	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
2024-10-24	Iniziato	UBS	Buy
2024-07-29	Downgrade	Piper Sandler	Overweight → Neutral
2023-11-20	Iniziato	Goldman	Buy
2023-09-18	Reiterato	Barclays	Overweight
2023-05-30	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-03-27	Ripresa	Wells Fargo	Equal Weight
2023-01-27	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-12-09	Downgrade	Goldman	Buy → Neutral
2022-10-31	Iniziato	Guggenheim	Neutral
2022-08-18	Ripresa	Wells Fargo	Equal Weight
2022-01-28	Aggiornamento	Stifel	Hold → Buy
2021-12-07	Ripresa	Cowen	Outperform
2021-06-10	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform
2021-05-20	Downgrade	Piper Sandler	Overweight → Neutral
2021-05-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2021-05-19	Downgrade	Stifel	Buy → Hold
2021-05-03	Iniziato	Truist	Buy
2021-04-16	Iniziato	Goldman	Buy
2021-03-08	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-12-15	Downgrade	H.C. Wainwright	Buy → Neutral
2020-10-06	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-04-22	Iniziato	Mizuho	Buy
2020-03-04	Iniziato	Barclays	Overweight
2020-02-26	Reiterato	H.C. Wainwright	Buy
2020-02-26	Reiterato	Oppenheimer	Outperform
2019-12-18	Iniziato	JMP Securities	Mkt Outperform
2019-10-01	Iniziato	Stifel	Buy
2019-04-29	Iniziato	Piper Jaffray	Overweight
2019-02-28	Reiterato	Chardan Capital Markets	Buy
2019-02-07	Iniziato	Robert W. Baird	Outperform
2018-12-31	Ripresa	B. Riley FBR	Buy
2018-07-06	Reiterato	Chardan Capital Markets	Buy
2018-04-10	Aggiornamento	B. Riley FBR, Inc.	Neutral → Buy
2018-03-13	Reiterato	B. Riley FBR, Inc.	Neutral
2018-02-23	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
2018-01-25	Reiterato	H.C. Wainwright	Buy
2017-11-01	Reiterato	B. Riley FBR, Inc.	Buy

Mostra tutto

Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie

Mar 04, 2026

RSU vesting boosts Iovance (NASDAQ: IOVA) CRO share holdings - Stock Titan

Mar 04, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Trading 9.9% Higher After Analyst Upgrade - MarketBeat

Mar 04, 2026

Iovance Biotherapeutics’ TIL Therapy Showcases Promising Results - StocksToTrade

Mar 04, 2026

Iovance Biotherapeutics: Short-Term Pain, Long-Term GainI'm Still Bullish After All These Years - Seeking Alpha

Mar 04, 2026

Iovance Biotherapeutics’ Stock Rallies After Promising Trial Data - timothysykes.com

Mar 04, 2026

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛

Mar 04, 2026

Mar 03, 2026

Citizens Upgrades Iovance Biotherapeutics (IOVA) - Nasdaq

Mar 03, 2026

Assessing Iovance Biotherapeutics (IOVA) Valuation After Amtagvi Momentum And New Fast Track Designation - Sahm

Mar 03, 2026

IOVA Receives Analyst Upgrade to Market Outperform by Citizens | - GuruFocus

Mar 03, 2026

Citizens Jmp Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to "Market Outperform" - MarketBeat

Mar 03, 2026

A Glimpse Into The Expert Outlook On Iovance Biotherapeutics Through 4 Analysts - Benzinga

Mar 03, 2026

This Unity Software Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday - Benzinga

Mar 03, 2026

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Short Interest Up 24.8% in February - MarketBeat

Mar 03, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Gains Visibility Across The Nasdaq Index - Kalkine Media

Mar 03, 2026

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Mar 03, 2026

Mar 02, 2026

IOVA: AMTAGVI drives robust growth as pipeline advances toward major milestones in lung and sarcoma - TradingView

Mar 02, 2026

Mar 01, 2026

symbol__ Stock Quote Price and Forecast - CNN

Mar 01, 2026

Feb 28, 2026

Iovance Lifileucel Progress Reshapes Growth Prospects Beyond Melanoma - Yahoo Finance

Feb 28, 2026

IOVA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Feb 28, 2026

Why Iovance Biotherapeutics (IOVA) Is Up 34.5% After Amtagvi-Fueled Revenue Jump And Lifileucel Fast Track - Sahm

Feb 28, 2026

Wall Street Zen Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to Hold - MarketBeat

Feb 28, 2026

Feb 27, 2026